drugset / Trial / NCT00140478
Mifepristone (RU-486) in Androgen Independent Prostate Cancer
Phase 2
Completed
48 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabGeorgetown University · collabMassachusetts General Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effects (good and bad) that mifepristone has on patients with androgen independent prostate cancer.
Timeline
- Start
- 2005-02
- Primary completion
- 2006-06
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mifepristone | Small molecule | 200 mg | Oral |